| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 274.4 | 4.7 |
| Profit before tax | 226.6 | -39.3 |
| Net income | 220.0 | -39.3 |
| EPS (diluted, $ a share) | $3.07 | $-0.62 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +5723.6% |
|---|---|
| Operating margin | 79.6% |
10-Q filed with the SEC, NASDAQ: PTGX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Protagonist Therapeutics, Inc: key numbers
- Share price
- $124.83Close, Nov 16
- Market cap
- $8.15B
- Shares outstanding
- 65.27MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Protagonist Therapeutics, Inc
All →Protagonist Therapeutics Financial Results
Protagonist Therapeutics reported Q3 2026 financial results, highlighted by the FDA approval of MIMRYLO (rusfertide) for polycythemia vera, which triggered $275 million in payments from partner Takeda. The company ended the quarter with $834.6 million in cash and announced a $300 million share repurchase program.
- Term
- Q3 2026
“The third quarter was a defining period for Protagonist, with FDA approval of MIMRYLO, our second approval this year for a first-in-class peptide drug, and the continued strong commercial launch of ICOTYDE under our collaboration with Johnson & Johnson.”
Dinesh V. Patel, PhD, President and Chief Executive Officer
“The partnerships are fueling an accelerating revenue engine, which provides the flexibility to fund the next generation of wholly owned programs emerging from our platform, and to return meaningful capital to shareholders through a share repurchase program.”
Dinesh V. Patel, PhD, President and Chief Executive Officer
Protagonist Therapeutics CFO Asif Ali Sells $8.31M of Stock
Asif Ali, CFO, sold 58,629 shares of Protagonist Therapeutics, Inc at $141.77 to $141.78 a share (average $141.78) in 2 transactions, worth $8.31M in total on Sep 30, 2026. Shares held after the trade: 59,003 (-43.8%).
- Value
- $8.31M
- Shares
- 58,629
- Average price
- $141.78
- Role
- CFO
- Holding change
- -43.8%
- Trade date
- Sep 30, 2026